Skip to main content

NUEVAS FUNCIONES DE LOS COMPLEJOS POLYCOMB EN REGULACION GENICA, ORGANIZACION DE LA CROMATINA Y EN CANCER

BFU2016-75008-P

•
Funding agency name Agencia Estatal de Investigación
Funding agency acronym AEI
Program Programa Estatal de Fomento de la Investigación Científica y Técnica de Excelencia
Subprogram Subprograma Estatal de Generación de Conocimiento
Call Proyectos de I+D (Excelencia / Generación de Conocimiento)
Call year 2016
State Plan 2013-2016 Plan Estatal de Investigación Científica y Técnica y de Innovación
Beneficiary centre FUNDACIO CENTRE DE REGULACIO GENOMICA

Resultados relacionados

Resultados totales (Incluyendo duplicados): 38
Encontrada(s) 1 página(s)

Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

PHF19 mediated regulation of proliferation and invasiveness in prostate cancer cells

  • Jain, Payal, 1986-
  • Ballaré, Cecilia Julia
  • Blanco, Enrique
  • Vizán, Pedro
  • Di Croce, Luciano
The Polycomb-like protein PHF19/PCL3 associates with PRC2 and mediates its recruitment to chromatin in embryonic stem cells. PHF19 is also overexpressed in many cancers. However, neither PHF19 targets nor misregulated pathways involving PHF19 are known. Here, we investigate the role of PHF19 in prostate cancer cells. We find that PHF19 interacts with PRC2 and binds to PRC2 targets on chromatin. PHF19 target genes are involved in proliferation, differentiation, angiogenesis, and extracellular matrix organization. Depletion of PHF19 triggers an increase in MTF2/PCL2 chromatin recruitment, with a genome-wide gain in PRC2 occupancy and H3K27me3 deposition. Transcriptome analysis shows that PHF19 loss promotes deregulation of key genes involved in growth, metastasis, invasion, and of factors that stimulate blood vessels formation. Consistent with this, PHF19 silencing reduces cell proliferation, while promotes invasive growth and angiogenesis. Our findings reveal a role for PHF19 in controlling the balance between cell proliferation and invasiveness in prostate cancer., This work was suported by the Spanish Ministry of Science and Innovation (BFU2016-75008-P), the Fundación Vencer El Cáncer, the European Regional Development Fund, the Fundación Científica Asociación Española Contra el Cáncer, the Fundació la Marató de TV3, the Agència de Gestió d’Ajuts Universitaris i de Recerca, the Generalitat de Catalunya (Secretaria d’Universitats i Recerca del Departament d’Economia i Coneixement), the Instituto de Salud Carlos III, the European Molecular Biology Laboratory, the Centro de Excelencia Severo Ochoa and the Generalitat de Catalunya (Centres de Recerca de Catalunya)
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Lamin B1 mapping reveals the existence of dynamic and functional euchromatin lamin B1 domains

  • Pascual-Reguant, Laura, 1990-
  • Blanco, Enrique
  • Galan Martínez, Silvia, 1992-
  • Le Dily, François
  • Cuartero, Yasmina
  • Serra Bardenys, Gemma, 1992-
  • Di Carlo, Valerio
  • Iturbide Martínez de Albéniz, Ane, 1989-
  • Cebrià i Costa, Joan Pau, 1989-
  • Nonell Mazelon, Lara, 1972-
  • García de Herreros, Antonio
  • Di Croce, Luciano
  • Martí Renom, Marc A.
  • Peiró Sales, Sandra
Lamins (A/C and B) are major constituents of the nuclear lamina (NL). Structurally conserved lamina-associated domains (LADs) are formed by genomic regions that contact the NL. Lamins are also found in the nucleoplasm, with a yet unknown function. Here we map the genome-wide localization of lamin B1 in an euchromatin-enriched fraction of the mouse genome and follow its dynamics during the epithelial-to-mesenchymal transition (EMT). Lamin B1 associates with actively expressed and open euchromatin regions, forming dynamic euchromatin lamin B1-associated domains (eLADs) of about 0.3 Mb. Hi-C data link eLADs to the 3D organization of the mouse genome during EMT and correlate lamin B1 enrichment at topologically associating domain (TAD) borders with increased border strength. Having reduced levels of lamin B1 alters the EMT transcriptional signature and compromises the acquisition of mesenchymal traits. Thus, during EMT, the process of genome reorganization in mouse involves dynamic changes in eLADs, This work was supported by grants from the Instituto de Salud Carlos III (ISCIII) FIS/FEDER (PI15/00396; CPII14/0006), Ministerio de Economía y Competitividad (MINECO) (SAF2013-40922-R1; FPU14/0407; BFU2016-75008-P), Agencia Estatal de Investigación (AEI) and Fondo Europeo de Desarrollo Regional-FEDER (SAF2016-76461-R), Generalitat de Catalunya (2014 SGR 32), Fundació FERO, Fundació La Marató TV3, and La Caixa Foundation. We also thank the Advanced Light Microscopy Unit at the CRG for their assistance and the Cellex Foundation for providing research facilities and equipment. M.A.M.-R. acknowledges funding from the European Research Council under the 7th Framework Program (FP7/2010-2015, ERC grant agreement 609989), the European Union’s Horizon 2020 research and innovation program (agreement 676556), the Spanish Ministry of Economy and Competitiveness (BFU2013-47736-P), and the Centro de Excelencia Severo Ochoa 2013-2017 (SEV-2012-0208) to the CRG
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Interplay between DNA and RNA modifications: a constantly evolving process

  • Di Croce, Luciano
  • Fico, Annalisa
  • Di Croce, Luciano
  • Matarazzo, Maria R.
The epigenome refers to the entirety of DNA methylations, histone modifications, nucleosome occupancy, and coding and non-coding RNAs (and their modifications) in different cell types [...]., This work is supported by Italian Ministry of Education-University-Research (CTN01_00177 Cluster ALISEI_IRMI) and AIRC (IG20736) to Annalisa Fico. The work in the Di Croce laboratory is supported by grants from the Spanish Ministry of Science and Innovation (BFU2016-75008-P, and PID2019-108322GB-100). The work in the Matarazzo laboratory is supported by the grant 2014-2020 FESR F/050011/01-02/X32 PON/MISE
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

The Polycomb group protein CBX6 is an essential regulator of embryonic stem cell identity

  • Santanach Buxaderas, Alexandra, 1988-
  • Blanco, Enrique
  • Jiang, Hua
  • Molloy, Kelly R.
  • Sansó Martínez, Miriam, 1979-
  • LaCava, John
  • Morey Ramonell, Lluís
  • Di Croce, Luciano
Polycomb group proteins (PcG) are transcriptional repressors that control cell identity and development. In mammals, five different CBX proteins associate with the core Polycomb repressive complex 1 (PRC1). In mouse embryonic stem cells (ESCs), CBX6 and CBX7 are the most highly expressed CBX family members. CBX7 has been recently characterized, but little is known regarding the function of CBX6. Here, we show that CBX6 is essential for ESC identity. Its depletion destabilizes the pluripotency network and triggers differentiation. Mechanistically, we find that CBX6 is physically and functionally associated to both canonical PRC1 (cPRC1) and non-canonical PRC1 (ncPRC1) complexes. Notably, in contrast to CBX7, CBX6 is recruited to chromatin independently of H3K27me3. Taken together, our findings reveal that CBX6 is an essential component of ESC biology that contributes to the structural and functional complexity of the PRC1 complex., This work was supported by grants from the Spanish Ministry of Economy and Competitiveness (BFU2016-75008-P), Centro de Excelencia Severo Ochoa 2013-2017 (SEV-2012-0208), AGAUR, Fundació “La Marató de TV3,” CERCA Programme/Generalitat de Catalunya, and EU FP7 Programs 4DCellFate (277899) to L.D.C. This work aided by collaboration with the National Center for Dynamic Interactome Research and the National Resource for the Mass Spectrometric Analysis of Biological Macromolecules, supported in part by NIH grant P41 GM109824 to Michael P. Rout and grant P41 GM103314 to Brian T. Chait. This paper is subject to the NIH Public Access Policy.
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Chromatin capture links the metabolic enzyme AHCY to stem cell proliferation

  • Aranda Aragón, Sergio
  • Alcaine Colet, Anna, 1992-
  • Blanco, Enrique
  • Borràs, Eva
  • Caillot, Claire
  • Sabidó Aguadé, Eduard, 1981-
  • Di Croce, Luciano
Profiling the chromatin-bound proteome (chromatome) in a simple, direct, and reliable manner might be key to uncovering the role of yet uncharacterized chromatin factors in physiology and disease. Here, we have designed an experimental strategy to survey the chromatome of proliferating cells by using the DNA-mediated chromatin pull-down (Dm-ChP) technology. Our approach provides a global view of cellular chromatome under normal physiological conditions and enables the identification of chromatin-bound proteins de novo. Integrating Dm-ChP with genomic and functional data, we have discovered an unexpected chromatin function for adenosylhomocysteinase, a major one-carbon pathway metabolic enzyme, in gene activation. Our study reveals a new regulatory axis between the metabolic state of pluripotent cells, ribosomal protein production, and cell division during the early phase of embryo development, in which the metabolic flux of methylation reactions is favored in a local milieu., We acknowledge support from the Spanish Ministry of Economy, Industry and Competitiveness to the EMBL partnership, Centro de Excelencia Severo Ochoa, the CERCA Programme/Generalitat de Catalunya, the Secretary for Universities and Research of the Ministry of Economy and Knowledge of the Government of Catalonia (to S.A. and A.A.-C.). The CRG/UPF Proteomics Unit is a member of the ProteoRed PRB3 consortium that was supported by grant PT17/0019 of the PE I+D+i 2013–2016 from the Instituto de Salud Carlos III (ISCIII), ERDF, and “Secretaria d’Universitats i Recerca del Departament d’Economia i Coneixement de la Generalitat de Catalunya” (2017SGR595). The Di Croce Laboratory was supported by grants from the Spanish Ministerio de Educación y Ciencia (BFU2016-75008-P), AGAUR, and La Marato TV3
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Differential contribution to gene expression prediction of histone modifications at enhancers or promoters

  • González Ramírez, Mar, 1991-
  • Ballaré, Cecilia Julia
  • Mugianesi, Francesca
  • Beringer, Malte
  • Santanach Buxaderas, Alexandra, 1988-
  • Blanco, Enrique
  • Di Croce, Luciano
The ChIP-seq signal of histone modifications at promoters is a good predictor of gene expression in different cellular contexts, but whether this is also true at enhancers is not clear. To address this issue, we develop quantitative models to characterize the relationship of gene expression with histone modifications at enhancers or promoters. We use embryonic stem cells (ESCs), which contain a full spectrum of active and repressed (poised) enhancers, to train predictive models. As many poised enhancers in ESCs switch towards an active state during differentiation, predictive models can also be trained on poised enhancers throughout differentiation and in development. Remarkably, we determine that histone modifications at enhancers, as well as promoters, are predictive of gene expression in ESCs and throughout differentiation and development. Importantly, we demonstrate that their contribution to the predictive models varies depending on their location in enhancers or promoters. Moreover, we use a local regression (LOESS) to normalize sequencing data from different sources, which allows us to apply predictive models trained in a specific cellular context to a different one. We conclude that the relationship between gene expression and histone modifications at enhancers is universal and different from promoters. Our study provides new insight into how histone modifications relate to gene expression based on their location in enhancers or promoters., The work in the Di Croce laboratory is supported by grants from the Spanish Ministry of Science and Innovation (BFU2016-75008-P, and PID2019-108322GB-100), “Fundación Vencer El Cancer” (VEC), the European Regional Development Fund (FEDER), and from AGAUR (SGR 2017-2019, AGAUR 2019 FI_B 00426). We acknowledge support from the Spanish Ministry of Science and Innovation to the EMBL partnership, the Centro de Excelencia Severo Ochoa and the CERCA Programme/Generalitat de Catalunya
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

SpikChIP: a novel computational methodology to compare multiple ChIP-seq using spike-in chromatin

  • Blanco, Enrique
  • Di Croce, Luciano
  • Aranda Aragón, Sergio
In order to evaluate cell- and disease-specific changes in the interacting strength of chromatin targets, ChIP-seq signal across multiple conditions must undergo robust normalization. However, this is not possible using the standard ChIP-seq scheme, which lacks a reference for the control of biological and experimental variabilities. While several studies have recently proposed different solutions to circumvent this problem, substantial analytical differences among methodologies could hamper the experimental reproducibility and quantitative accuracy. Here, we propose a computational method to accurately compare ChIP-seq experiments, with exogenous spike-in chromatin, across samples in a genome-wide manner by using a local regression strategy (spikChIP). In contrast to the previous methodologies, spikChIP reduces the influence of sequencing noise of spike-in material during ChIP-seq normalization, while minimizes the overcorrection of non-occupied genomic regions in the experimental ChIP-seq. We demonstrate the utility of spikChIP with both histone and non-histone chromatin protein, allowing us to monitor for experimental reproducibility and the accurate ChIP-seq comparison of distinct experimental schemes. spikChIP software is available on GitHub (https://github.com/eblancoga/spikChIP)., Spanish of Economy, Industry and Competitiveness (MEIC) (BFU2016-75008-P, and PID2019-108322GB-100), “Fundación Vencer El Cancer” (VEC), the European Regional Development Fund (FEDER), and from AGAUR to L.D.C. The Ramon y Cajal program of the Ministerio de Ciencia, Innovación y Universidades and the European Social Fund under the reference number RYC-2018-025002-I, and the Instituto de Salud Carlos III-FEDER (PI19/01814), to S.A. We acknowledge the funding support of the Spanish Ministry of Science and Innovation to the EMBL partnership, the Centro de Excelencia Severo Ochoa and the CERCA Programme / Generalitat de Catalunya.
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Polycomb factor PHF19 controls cell growth and differentiation toward erythroid pathway in chronic myeloid leukemia cells

  • García Montolío, Marc, 1991-
  • Ballaré, Cecilia Julia
  • Blanco, Enrique
  • Gutiérrez, Arantxa
  • Aranda Aragón, Sergio
  • Gómez, Antonio
  • Kok, Chung H.
  • Yeung, David T.
  • Hughes, Timothy P.
  • Vizán, Pedro
  • Di Croce, Luciano
Polycomb group (PcG) of proteins are a group of highly conserved epigenetic regulators involved in many biological functions, such as embryonic development, cell proliferation, and adult stem cell determination. PHD finger protein 19 (PHF19) is an associated factor of Polycomb repressor complex 2 (PRC2), often upregulated in human cancers. In particular, myeloid leukemia cell lines show increased levels of PHF19, yet little is known about its function. Here, we have characterized the role of PHF19 in myeloid leukemia cells. We demonstrated that PHF19 depletion decreases cell proliferation and promotes chronic myeloid leukemia (CML) differentiation. Mechanistically, we have shown how PHF19 regulates the proliferation of CML through a direct regulation of the cell cycle inhibitor p21. Furthermore, we observed that MTF2, a PHF19 homolog, partially compensates for PHF19 depletion in a subset of target genes, instructing specific erythroid differentiation. Taken together, our results show that PHF19 is a key transcriptional regulator for cell fate determination and could be a potential therapeutic target for myeloid leukemia treatment., This work was supported by grants from the Spanish Ministry of Science and Innovation (BFU2016-75008-P and PID2019-108322GB-100), “Fundación Vencer El Cancer” (VEC), the European Regional Development Fund (FEDER), and from AGAUR (SGR 2017-2019). SA was funded by the Ramon y Cajal program of the Ministerio de Ciencia, Innovación y Universidades, the European Social Fund under the reference number RYC-2018-025002-I, and the Instituto de Salud Carlos III-FEDER (PI19/01814)
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Trans-generational epigenetic regulation associated with the amelioration of Duchenne Muscular Dystrophy

  • Martone, Julie
  • Lisi, Michela
  • Castagnetti, Francesco
  • Rosa, Alessandro
  • Di Carlo, Valerio
  • Blanco, Enrique
  • Setti, Adriano
  • Mariani, Davide
  • Colantoni, Alessio
  • Santini, Tiziana
  • Perone, Lucia
  • Di Croce, Luciano
  • Bozzoni, Irene
Exon skipping is an effective strategy for the treatment of many Duchenne Muscular Dystrophy (DMD) mutations. Natural exon skipping observed in several DMD cases can help in identifying novel therapeutic tools. Here, we show a DMD study case where the lack of a splicing factor (Celf2a), which results in exon skipping and dystrophin rescue, is due to a maternally inherited trans-generational epigenetic silencing. We found that the study case and his mother express a repressive long non-coding RNA, DUXAP8, whose presence correlates with silencing of the Celf2a coding region. We also demonstrate that DUXAP8 expression is lost upon cell reprogramming and that, upon induction of iPSCs into myoblasts, Celf2a expression is recovered leading to the loss of exon skipping and loss of dystrophin synthesis. Finally, CRISPR/Cas9 inactivation of the splicing factor Celf2a was proven to ameliorate the pathological state in other DMD backgrounds establishing Celf2a ablation or inactivation as a novel therapeutic approach for the treatment of Duchenne Muscular Dystrophy., This work was partially supported by grants from ERC‐2019‐SyG (855923‐ASTRA), Telethon (GGP16213), Parent Project Italia, AIRC (IG 2019 Id. 23053) and PRIN 2017 (2017P352Z4) to I.B.; Spanish Ministry of Economy, Industry and Competitiveness (MEIC) (BFU2016‐75008‐P) to L.D.C. and Sapienza Research Calls (RM118164363B1D21) to J.M.
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Chromatin-bound proteome profiling by genome capture

  • Aranda Aragón, Sergio
  • Borràs, Eva
  • Sabidó Aguadé, Eduard, 1981-
  • Di Croce, Luciano
De novo identification of chromatin interactors can reveal unexpected pathways relevant to physiology and human disease. Inspired by the DNA mediated chromatin pull-down (Dm-ChP) technology (also known as iPOND [isolation of proteins on nascent DNA]) for the proteomic characterization of nascent DNA, we have recently reported a new experimental protocol that allows for the identification of proteins on total DNA (iPOTD) for bulk chromatome profiling and de novo identification of chromatin-bound proteins. Here, we detail a step-by-step protocol to survey the cellular chromatin-bound proteome in a simple, robust, and unbiased manner. For complete details on the use and execution of this protocol, please refer to Aranda et al. (2019)., The Proteomics Unit is supported by EPIC-XS, project number 823839, funded by the Horizon 2020 programme of the European Union. The Di Croce Laboratory is supported by grants from the Spanish Ministerio de Educación y Ciencia (BFU2016-75008-P) and by AGAUR.
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

The changing chromatome as a driver of disease: a panoramic view from different methodologies

  • Espejo, Isabel
  • Di Croce, Luciano
  • Aranda Aragón, Sergio
Chromatin-bound proteins underlie several fundamental cellular functions, such as control of gene expression and the faithful transmission of genetic and epigenetic information. Components of the chromatin proteome (the "chromatome") are essential in human life, and mutations in chromatin-bound proteins are frequently drivers of human diseases, such as cancer. Proteomic characterization of chromatin and de novo identification of chromatin interactors could, thus, reveal important and perhaps unexpected players implicated in human physiology and disease. Recently, intensive research efforts have focused on developing strategies to characterize the chromatome composition. In this review, we provide an overview of the dynamic composition of the chromatome, highlight the importance of its alterations as a driving force in human disease (and particularly in cancer), and discuss the different approaches to systematically characterize the chromatin-bound proteome in a global manner., I.E. is supported by La CaixaINPhINIT program. L.D.C is supported by grants from the Spanish of Economy, Industry and Competitiveness (MEIC) (BFU2016‐75008‐P), “FundaciónVencer El Cancer” (VEC), the European Regional Development Fund (FEDER), Fundació “La Marató de TV3”, and from AGAUR. S.A. is funded by Ramón y Cajal Program MICIU‐FSE (RYC2018‐025002‐I) and ISCIII‐FEDER (PI19/01814)
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Polycomb complexes in normal and malignant hematopoiesis

  • Di Carlo, Valerio
  • Mocavini, Ivano
  • Di Croce, Luciano
Epigenetic mechanisms are crucial for sustaining cell type-specific transcription programs. Among the distinct factors, Polycomb group (PcG) proteins are major negative regulators of gene expression in mammals. These proteins play key roles in regulating the proliferation, self-renewal, and differentiation of stem cells. During hematopoietic differentiation, many PcG proteins are fundamental for proper lineage commitment, as highlighted by the fact that a lack of distinct PcG proteins results in embryonic lethality accompanied by differentiation biases. Correspondingly, proteins of these complexes are frequently dysregulated in hematological diseases. In this review, we present an overview of the role of PcG proteins in normal and malignant hematopoiesis, focusing on the compositional complexity of PcG complexes, and we briefly discuss the ongoing clinical trials for drugs targeting these factors., Support to the Di Croce laboratory comes from grants from the Spanish Ministry of Economy, Industry, and Competitiveness (BFU2016-75008-P), the European Regional Development Fund (FEDER), Fundacion Vencer El Cancer, and Agència de Gestió d’Ajuts Universitaris i de Recerca; to V. Di Carlo from an ImPuLSe Marie Curie Postdoctoral Fellowship of the European Union Seventh Framework Program (FP7/2007-2013; grant 608959); and I. Mocavini from an FPI fellowship. We acknowledge support of the Spanish Ministry of Economy, Industry, and Competitiveness through the Instituto de Salud Carlos III and for the European Molecular Biology Laboratory partnership; Centro de Excelencia Severo Ochoa; and the Centres de Recerca de Catalunya Program/Generalitat de Catalunya.
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

RING1B recruits EWSR1-FLI1 and cooperates in the remodeling of chromatin necessary for Ewing sarcoma tumorigenesis

  • Sánchez-Molina, Sara
  • Figuerola, Elisabeth
  • Blanco, Enrique
  • Sánchez-Jiménez, María
  • Táboas, Pablo
  • Gómez, Soledad
  • Ballaré, Cecilia Julia
  • García-Domínguez, Daniel J.
  • Prada, Estela
  • Hontecillas-Prieto, Lourdes
  • Carcaboso, Angel M.
  • Tirado, Oscar M.
  • Hernández Muñoz, María Inmaculada
  • Alava, Enrique de
  • Lavarino, Cinzia
  • Di Croce, Luciano
  • Mora, Jaume
Ewing sarcoma (EwS) is an aggressive tumor that affects adolescents and young adults. EwS is defined by a chromosomal translocation, EWSR1-FLI1 being the most common, that causes genome reprogramming through remodeling of enhancers. Here, we describe an unexpected function of RING1B, which is highly expressed in EwS. While retaining its repressive activity at Polycomb developmental regulated genes, RING1B colocalizes with EWSR1-FLI1 at active enhancers. We demonstrate that RING1B is necessary for the expression of key EWSR1-FLI1 targets by facilitating oncogene recruitment to their enhancers. Knockdown of RING1B impairs growth of tumor xenografts and expression of genes regulated by EWSR1-FLI1 bound enhancers. Pharmacological inhibition of AURKB with AZD1152 increases H2Aub levels causing down-regulation of RING1B/EWSR1-FLI1 common targets. Our findings demonstrate that RING1B is a critical modulator of EWSR1-FLI1-induced chromatin remodeling, and its inhibition is a potential therapeutic strategy for the treatment of these tumors., S.S.-M. and the project were supported by the Spanish Association Against Cancer (AECC) consolidated groups grant (GCB13131578) consortium. The project also had the support from the Asociacion Pablo Ugarte (APU). E.F.-B. was supported by the Spanish government grant, Instituto de Salud Carlos III (PI16/00245) to J.M. The work in the Di Croce laboratory was supported by grants from the Spanish of Economy, Industry and Competitiveness (MEIC) (BFU2016-75008-P), and Fundacion Vencer El Cancer (VEC).
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Epigenomic profiling of primate lymphoblastoid cell lines reveals the evolutionary patterns of epigenetic activities in gene regulatory architectures

  • García Pérez, Raquel, 1989-
  • Esteller Cucala, Paula
  • Mas, Glòria
  • Lobon Garcia, Irene
  • Di Carlo, Valerio
  • Riera, Meritxell
  • Kuhlwilm, Martin
  • Navarro i Cuartiellas, Arcadi, 1969-
  • Blancher, Antoine
  • Di Croce, Luciano
  • Gómez Skarmeta, José Luis
  • Juan, David
  • Marquès i Bonet, Tomàs, 1975-
Changes in the epigenetic regulation of gene expression have a central role in evolution. Here, we extensively profiled a panel of human, chimpanzee, gorilla, orangutan, and macaque lymphoblastoid cell lines (LCLs), using ChIP-seq for five histone marks, ATAC-seq and RNA-seq, further complemented with whole genome sequencing (WGS) and whole genome bisulfite sequencing (WGBS). We annotated regulatory elements (RE) and integrated chromatin contact maps to define gene regulatory architectures, creating the largest catalog of RE in primates to date. We report that epigenetic conservation and its correlation with sequence conservation in primates depends on the activity state of the regulatory element. Our gene regulatory architectures reveal the coordination of different types of components and highlight the role of promoters and intragenic enhancers (gE) in the regulation of gene expression. We observe that most regulatory changes occur in weakly active gE. Remarkably, novel human-specific gE with weak activities are enriched in human-specific nucleotide changes. These elements appear in genes with signals of positive selection and human acceleration, tissue-specific expression, and particular functional enrichments, suggesting that the regulatory evolution of these genes may have contributed to human adaptation., R.G.-P. was supported by a fellowship from MICINN (FPU13/01823). P.E.-C. was supported by a Formació de Personal Investigador fellowship from Generalitat de Catalunya (FI_B00122). M.K. was supported by a Deutsche Forschungsgemeinschaft (DFG) fellowship (KU 3467/1-1) and the Postdoctoral Junior Leader Fellowship Program from “la Caixa” Banking Foundation (LCF/BQ/PR19/11700002). D.J. was supported by a Juan de la Cierva fellowship (FJCI2016-29558) from MICINN. T.M-B. is supported by funding from the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation program (grant agreement EC-H2020-ERC-CoG-ApeGenomeDiversity-864203), BFU2017-86471-P (AEI/FEDER, UE), “Unidad de Excelencia María de Maeztu”, funded by the AEI (CEX2018-000792-M), Howard Hughes International Early Career, NIH 1R01HG010898-01A1, Obra Social “La Caixa” and Secretaria d’Universitats i Recerca and CERCA Program del Departament d’Economia i Coneixement de la Generalitat de Catalunya (GRC 2017 SGR 880). G.M., V.D.C., and L.D.C. were supported by grants from the Spanish of Economy, Industry, and Competitiveness (MEIC) (BFU2016-75008-P) and G.M. was also supported by the “Convocatoria de Ayudas Fundación BBVA a Investigadores, Innovadores y Creadores Culturales”. J.L.G.-S. was supported by the Spanish government (grants BFU2016-74961-P), an institutional grant Unidad de Excelencia María de Maeztu (MDM-2016-0687) and the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation programme (grant agreement No 740041). A.N. was supported by Fondo Europeo de Desarrollo Regional (FEDER) with project grants BFU2016-77961-P and PGC2018- 101927-B-I00 and by the Spanish National Institute of Bioinformatics (PT17/0009/0020).
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

The Polycomb-associated factor PHF19 controls hematopoietic stem cell state and differentiation

  • Vizán, Pedro
  • Gutiérrez, Arantxa
  • Espejo, Isabel
  • García Montolío, Marc, 1991-
  • Lange, Martin
  • Carretero, Ana
  • Lafzi, Atefeh
  • Andrés Aguayo, Luisa de
  • Blanco, Enrique
  • Thambyrajah, Roshana
  • Graf, T. (Thomas)
  • Heyn, Holger
  • Bigas Salvans, Anna
  • Di Croce, Luciano
Adult hematopoietic stem cells (HSCs) are rare multipotent cells in bone marrow that are responsible for generating all blood cell types. HSCs are a heterogeneous group of cells with high plasticity, in part, conferred by epigenetic mechanisms. PHF19, a subunit of the Polycomb repressive complex 2 (PRC2), is preferentially expressed in mouse hematopoietic precursors. Here, we now show that, in stark contrast to results published for other PRC2 subunits, genetic depletion of Phf19 increases HSC identity and quiescence. While proliferation of HSCs is normally triggered by forced mobilization, defects in differentiation impede long-term correct blood production, eventually leading to aberrant hematopoiesis. At molecular level, PHF19 deletion triggers a redistribution of the histone repressive mark H3K27me3, which notably accumulates at blood lineage-specific genes. Our results provide novel insights into how epigenetic mechanisms determine HSC identity, control differentiation, and are key for proper hematopoiesis., The work in the Di Croce laboratory is supported by grants from the Spanish of Economy, Industry, and Competitiveness (MEIC) (BFU2016-75008-P), “Fundación Vencer El Cancer” (VEC), the European Regional Development Fund (FEDER), Fundació “La Marató de TV3,” and from AGAUR. The laboratory of A.B. is supported by SAF2016-75613-R from the Ministerio de Ciencia, Innovación y Universidades. H.H. is a Miguel Servet (CP14/00229) researcher funded by the Spanish Institute of Health Carlos III (ISCIII) and received funding from the European Union’s Horizon 2020 research and innovation programme (MSCA-ITN-2015-675752) and the Ministerio de Ciencia, Innovación y Universidades (SAF2017-89109-P; AEI/FEDER, UE). P.V. was supported by “Fundación Científica de la Asociación Española Contra el Cáncer.”
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

The bivalent genome: characterization, structure, and regulation

  • Blanco, Enrique
  • González Ramírez, Mar, 1991-
  • Alcaine Colet, Anna, 1992-
  • Aranda Aragón, Sergio
  • Di Croce, Luciano
An intricate molecular machinery is at the core of gene expression regulation in every cell. During the initial stages of organismal development, the coordinated activation of diverse transcriptional programs is crucial and must be carefully executed to shape every organ and tissue. Bivalent promoters and poised enhancers are regulatory regions decorated with histone marks that are associated with both positive and negative transcriptional outcomes. These apparently contradictory signals are important for setting bivalent genes in a poised state, which is subsequently resolved during differentiation into either active or repressive states. We discuss the origins of bivalent promoters and the mechanisms implicated in their acquisition and maintenance. We further review how the presence of bivalent marks influences genome architecture. Finally, we highlight the potential link between bivalency and cancer which could drive biomedical research in disease etiology and treatment., Work in the laboratory of L.D.C. is supported by grants from the Spanish of Economy, Industry, and Competitiveness (MEIC; BFU2016-75008-P), the Fundacion Vencer El Cancer (VEC), the European Regional Development Fund (FEDER), and the Catalan Agency for Management of University and Research Grants (AGAUR). We also acknowledge support from the MEIC (through the Instituto de Salud Carlos III and an EMBL partnership), the Centro de Excelencia Severo Ochoa, and the CERCA Programme/Generalitat de Catalunya.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

RING1B recruits EWSR1-FLI1 and cooperates in the remodeling of chromatin necessary for Ewing sarcoma tumorigenesis

  • Sánchez-Molina, Sara
  • Figuerola-Bou, Elisabet
  • Blanco, Enrique
  • Sánchez-Jiménez, María
  • Táboas, Pablo
  • Gómez, Soledad
  • Ballaré, Cecilia
  • García-Domínguez, D. J.
  • Prada, Estela
  • Hontecillas-Prieto, Lourdes
  • Carcaboso, Ángel M.
  • Tirado, Óscar M.
  • Hernández-Muñoz, Inmaculada
  • Álava, Enrique de
  • Lavarino, Cinzia
  • Di Croce, Luciano
  • Mora, Jaume
Ewing sarcoma (EwS) is an aggressive tumor that affects adolescents and young adults. EwS is defined by a chromosomal translocation, EWSR1-FLI1 being the most common, that causes genome reprogramming through remodeling of enhancers. Here, we describe an unexpected function of RING1B, which is highly expressed in EwS. While retaining its repressive activity at Polycomb developmental regulated genes, RING1B colocalizes with EWSR1-FLI1 at active enhancers. We demonstrate that RING1B is necessary for the expression of key EWSR1-FLI1 targets by facilitating oncogene recruitment to their enhancers. Knockdown of RING1B impairs growth of tumor xenografts and expression of genes regulated by EWSR1-FLI1 bound enhancers. Pharmacological inhibition of AURKB with AZD1152 increases H2Aub levels causing down-regulation of RING1B/EWSR1-FLI1 common targets. Our findings demonstrate that RING1B is a critical modulator of EWSR1-FLI1–induced chromatin remodeling, and its inhibition is a potential therapeutic strategy for the treatment of these tumors., S.S.-M. and the project were supported by the Spanish Association Against Cancer (AECC) consolidated groups grant (GCB13131578) consortium. The project also had the support from the Asociacion Pablo Ugarte (APU). E.F.-B. was supported by the Spanish government grant, Instituto de Salud Carlos III (PI16/00245) to J.M. The work in the Di Croce laboratory was supported by grants from the Spanish of Economy, Industry and Competitiveness (MEIC) (BFU2016-75008-P), and Fundacion Vencer El Cancer (VEC).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Epigenomic profiling of primate lymphoblastoid cell lines reveals the evolutionary patterns of epigenetic activities in gene regulatory architectures

  • García-Pérez, Raquel
  • Esteller-Cucala, Paula
  • Mas, Glòria
  • Lobón, Irene
  • Di Carlo, Valerio
  • Riera, Meritxell
  • Kuhlwilm, Martin
  • Navarro, Arcadi
  • Blancher, Antoine
  • Croce, Luciano di
  • Gómez-Skarmeta, José Luis
  • Juan, David
  • Marqués-Bonet, Tomàs
Changes in the epigenetic regulation of gene expression have a central role in evolution. Here, we extensively profiled a panel of human, chimpanzee, gorilla, orangutan, and macaque lymphoblastoid cell lines (LCLs), using ChIP-seq for five histone marks, ATAC-seq and RNA-seq, further complemented with whole genome sequencing (WGS) and whole genome bisulfite sequencing (WGBS). We annotated regulatory elements (RE) and integrated chromatin contact maps to define gene regulatory architectures, creating the largest catalog of RE in primates to date. We report that epigenetic conservation and its correlation with sequence conservation in primates depends on the activity state of the regulatory element. Our gene regulatory architectures reveal the coordination of different types of components and highlight the role of promoters and intragenic enhancers (gE) in the regulation of gene expression. We observe that most regulatory changes occur in weakly active gE. Remarkably, novel human-specific gE with weak activities are enriched in human-specific nucleotide changes. These elements appear in genes with signals of positive selection and human acceleration, tissue-specific expression, and particular functional enrichments, suggesting that the regulatory evolution of these genes may have contributed to human adaptation., R.G.-P. was supported by a fellowship from MICINN (FPU13/01823). P.E.-C. was supported by a Formació de Personal Investigador fellowship from Generalitat de Catalunya (FI_B00122). M.K. was supported by a Deutsche Forschungsgemeinschaft (DFG) fellowship (KU 3467/1-1) and the Postdoctoral Junior Leader Fellowship Program from “la Caixa” Banking Foundation (LCF/BQ/PR19/11700002). D.J. was supported by a Juan de la Cierva fellowship (FJCI2016-29558) from MICINN. T.M-B. is supported by funding from the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation program (grant agreement EC-H2020-ERC-CoG-ApeGenomeDiversity-864203), BFU2017-86471-P (AEI/FEDER, UE), “Unidad de Excelencia María de Maeztu”, funded by the AEI (CEX2018-000792-M), Howard Hughes International Early Career, NIH 1R01HG010898-01A1, Obra Social “La Caixa” and Secretaria d’Universitats i Recerca and CERCA Program del Departament d’Economia i Coneixement de la Generalitat de Catalunya (GRC 2017 SGR 880). G.M., V.D.C., and L.D.C. were supported by grants from the Spanish of Economy, Industry, and Competitiveness (MEIC) (BFU2016-75008-P) and G.M. was also supported by the “Convocatoria de Ayudas Fundación BBVA a Investigadores, Innovadores y Creadores Culturales”. J.L.G.-S. was supported by the Spanish government (grants BFU2016-74961-P), an institutional grant Unidad de Excelencia María de Maeztu (MDM-2016-0687) and the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation programme (grant agreement No 740041). A.N. was supported by Fondo Europeo de Desarrollo Regional (FEDER) with project grants BFU2016-77961-P and PGC2018- 101927-B-I00 and by the Spanish National Institute of Bioinformatics (PT17/0009/0020)., With funding from the Spanish government through the "Severo Ochoa Centre of Excellence" accreditation (CEX2018-000792-M)., Peer reviewed
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

RING1B recruits EWSR1-FLI1 and cooperates in the remodeling of chromatin necessary for Ewing sarcoma tumorigenesis

  • Sánchez-Molina, Sara
  • Figuerola, Elisabeth
  • Blanco, Enrique
  • Sánchez-Jiménez, María
  • Táboas, Pablo
  • Gómez, Soledad
  • Ballaré, Cecilia Julia
  • García-Domínguez, Daniel J.
  • Prada, Estela
  • Hontecillas-Prieto, Lourdes
  • Carcaboso, Angel M.
  • Tirado, Oscar M.
  • Hernández Muñoz, María Inmaculada
  • Alava, Enrique de
  • Lavarino, Cinzia
  • Di Croce, Luciano
  • Mora, Jaume
Ewing sarcoma (EwS) is an aggressive tumor that affects adolescents and young adults. EwS is defined by a chromosomal translocation, EWSR1-FLI1 being the most common, that causes genome reprogramming through remodeling of enhancers. Here, we describe an unexpected function of RING1B, which is highly expressed in EwS. While retaining its repressive activity at Polycomb developmental regulated genes, RING1B colocalizes with EWSR1-FLI1 at active enhancers. We demonstrate that RING1B is necessary for the expression of key EWSR1-FLI1 targets by facilitating oncogene recruitment to their enhancers. Knockdown of RING1B impairs growth of tumor xenografts and expression of genes regulated by EWSR1-FLI1 bound enhancers. Pharmacological inhibition of AURKB with AZD1152 increases H2Aub levels causing down-regulation of RING1B/EWSR1-FLI1 common targets. Our findings demonstrate that RING1B is a critical modulator of EWSR1-FLI1-induced chromatin remodeling, and its inhibition is a potential therapeutic strategy for the treatment of these tumors., S.S.-M. and the project were supported by the Spanish Association Against Cancer (AECC) consolidated groups grant (GCB13131578) consortium. The project also had the support from the Asociacion Pablo Ugarte (APU). E.F.-B. was supported by the Spanish government grant, Instituto de Salud Carlos III (PI16/00245) to J.M. The work in the Di Croce laboratory was supported by grants from the Spanish of Economy, Industry and Competitiveness (MEIC) (BFU2016-75008-P), and Fundacion Vencer El Cancer (VEC).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Differential contribution to gene expression prediction of histone modifications at enhancers or promoters

  • González Ramírez, Mar, 1991-
  • Ballaré, Cecilia Julia
  • Mugianesi, Francesca
  • Beringer, Malte
  • Santanach Buxaderas, Alexandra, 1988-
  • Blanco, Enrique
  • Di Croce, Luciano
The ChIP-seq signal of histone modifications at promoters is a good predictor of gene expression in different cellular contexts, but whether this is also true at enhancers is not clear. To address this issue, we develop quantitative models to characterize the relationship of gene expression with histone modifications at enhancers or promoters. We use embryonic stem cells (ESCs), which contain a full spectrum of active and repressed (poised) enhancers, to train predictive models. As many poised enhancers in ESCs switch towards an active state during differentiation, predictive models can also be trained on poised enhancers throughout differentiation and in development. Remarkably, we determine that histone modifications at enhancers, as well as promoters, are predictive of gene expression in ESCs and throughout differentiation and development. Importantly, we demonstrate that their contribution to the predictive models varies depending on their location in enhancers or promoters. Moreover, we use a local regression (LOESS) to normalize sequencing data from different sources, which allows us to apply predictive models trained in a specific cellular context to a different one. We conclude that the relationship between gene expression and histone modifications at enhancers is universal and different from promoters. Our study provides new insight into how histone modifications relate to gene expression based on their location in enhancers or promoters., The work in the Di Croce laboratory is supported by grants from the Spanish Ministry of Science and Innovation (BFU2016-75008-P, and PID2019-108322GB-100), “Fundación Vencer El Cancer” (VEC), the European Regional Development Fund (FEDER), and from AGAUR (SGR 2017-2019, AGAUR 2019 FI_B 00426). We acknowledge support from the Spanish Ministry of Science and Innovation to the EMBL partnership, the Centro de Excelencia Severo Ochoa and the CERCA Programme/Generalitat de Catalunya
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Lamin B1 mapping reveals the existence of dynamic and functional euchromatin lamin B1 domains

  • Pascual-Reguant, Laura, 1990-
  • Blanco, Enrique
  • Galan Martínez, Silvia, 1992-
  • Le Dily, François
  • Cuartero, Yasmina
  • Serra Bardenys, Gemma, 1992-
  • Di Carlo, Valerio
  • Iturbide Martínez de Albéniz, Ane, 1989-
  • Cebrià i Costa, Joan Pau, 1989-
  • Nonell Mazelon, Lara, 1972-
  • García de Herreros, Antonio
  • Di Croce, Luciano
  • Martí Renom, Marc A.
  • Peiró Sales, Sandra
Lamins (A/C and B) are major constituents of the nuclear lamina (NL). Structurally conserved lamina-associated domains (LADs) are formed by genomic regions that contact the NL. Lamins are also found in the nucleoplasm, with a yet unknown function. Here we map the genome-wide localization of lamin B1 in an euchromatin-enriched fraction of the mouse genome and follow its dynamics during the epithelial-to-mesenchymal transition (EMT). Lamin B1 associates with actively expressed and open euchromatin regions, forming dynamic euchromatin lamin B1-associated domains (eLADs) of about 0.3 Mb. Hi-C data link eLADs to the 3D organization of the mouse genome during EMT and correlate lamin B1 enrichment at topologically associating domain (TAD) borders with increased border strength. Having reduced levels of lamin B1 alters the EMT transcriptional signature and compromises the acquisition of mesenchymal traits. Thus, during EMT, the process of genome reorganization in mouse involves dynamic changes in eLADs, This work was supported by grants from the Instituto de Salud Carlos III (ISCIII) FIS/FEDER (PI15/00396; CPII14/0006), Ministerio de Economía y Competitividad (MINECO) (SAF2013-40922-R1; FPU14/0407; BFU2016-75008-P), Agencia Estatal de Investigación (AEI) and Fondo Europeo de Desarrollo Regional-FEDER (SAF2016-76461-R), Generalitat de Catalunya (2014 SGR 32), Fundació FERO, Fundació La Marató TV3, and La Caixa Foundation. We also thank the Advanced Light Microscopy Unit at the CRG for their assistance and the Cellex Foundation for providing research facilities and equipment. M.A.M.-R. acknowledges funding from the European Research Council under the 7th Framework Program (FP7/2010-2015, ERC grant agreement 609989), the European Union’s Horizon 2020 research and innovation program (agreement 676556), the Spanish Ministry of Economy and Competitiveness (BFU2013-47736-P), and the Centro de Excelencia Severo Ochoa 2013-2017 (SEV-2012-0208) to the CRG
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Epigenomic profiling of primate lymphoblastoid cell lines reveals the evolutionary patterns of epigenetic activities in gene regulatory architectures

  • García Pérez, Raquel, 1989-
  • Esteller Cucala, Paula
  • Mas, Glòria
  • Lobon Garcia, Irene
  • Di Carlo, Valerio
  • Riera, Meritxell
  • Kuhlwilm, Martin
  • Navarro i Cuartiellas, Arcadi, 1969-
  • Blancher, Antoine
  • Di Croce, Luciano
  • Gómez Skarmeta, José Luis
  • Juan, David
  • Marquès i Bonet, Tomàs, 1975-
Changes in the epigenetic regulation of gene expression have a central role in evolution. Here, we extensively profiled a panel of human, chimpanzee, gorilla, orangutan, and macaque lymphoblastoid cell lines (LCLs), using ChIP-seq for five histone marks, ATAC-seq and RNA-seq, further complemented with whole genome sequencing (WGS) and whole genome bisulfite sequencing (WGBS). We annotated regulatory elements (RE) and integrated chromatin contact maps to define gene regulatory architectures, creating the largest catalog of RE in primates to date. We report that epigenetic conservation and its correlation with sequence conservation in primates depends on the activity state of the regulatory element. Our gene regulatory architectures reveal the coordination of different types of components and highlight the role of promoters and intragenic enhancers (gE) in the regulation of gene expression. We observe that most regulatory changes occur in weakly active gE. Remarkably, novel human-specific gE with weak activities are enriched in human-specific nucleotide changes. These elements appear in genes with signals of positive selection and human acceleration, tissue-specific expression, and particular functional enrichments, suggesting that the regulatory evolution of these genes may have contributed to human adaptation., R.G.-P. was supported by a fellowship from MICINN (FPU13/01823). P.E.-C. was supported by a Formació de Personal Investigador fellowship from Generalitat de Catalunya (FI_B00122). M.K. was supported by a Deutsche Forschungsgemeinschaft (DFG) fellowship (KU 3467/1-1) and the Postdoctoral Junior Leader Fellowship Program from “la Caixa” Banking Foundation (LCF/BQ/PR19/11700002). D.J. was supported by a Juan de la Cierva fellowship (FJCI2016-29558) from MICINN. T.M-B. is supported by funding from the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation program (grant agreement EC-H2020-ERC-CoG-ApeGenomeDiversity-864203), BFU2017-86471-P (AEI/FEDER, UE), “Unidad de Excelencia María de Maeztu”, funded by the AEI (CEX2018-000792-M), Howard Hughes International Early Career, NIH 1R01HG010898-01A1, Obra Social “La Caixa” and Secretaria d’Universitats i Recerca and CERCA Program del Departament d’Economia i Coneixement de la Generalitat de Catalunya (GRC 2017 SGR 880). G.M., V.D.C., and L.D.C. were supported by grants from the Spanish of Economy, Industry, and Competitiveness (MEIC) (BFU2016-75008-P) and G.M. was also supported by the “Convocatoria de Ayudas Fundación BBVA a Investigadores, Innovadores y Creadores Culturales”. J.L.G.-S. was supported by the Spanish government (grants BFU2016-74961-P), an institutional grant Unidad de Excelencia María de Maeztu (MDM-2016-0687) and the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation programme (grant agreement No 740041). A.N. was supported by Fondo Europeo de Desarrollo Regional (FEDER) with project grants BFU2016-77961-P and PGC2018- 101927-B-I00 and by the Spanish National Institute of Bioinformatics (PT17/0009/0020).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

PHF19 mediated regulation of proliferation and invasiveness in prostate cancer cells

  • Jain, Payal, 1986-
  • Ballaré, Cecilia Julia
  • Blanco, Enrique
  • Vizán, Pedro
  • Di Croce, Luciano
The Polycomb-like protein PHF19/PCL3 associates with PRC2 and mediates its recruitment to chromatin in embryonic stem cells. PHF19 is also overexpressed in many cancers. However, neither PHF19 targets nor misregulated pathways involving PHF19 are known. Here, we investigate the role of PHF19 in prostate cancer cells. We find that PHF19 interacts with PRC2 and binds to PRC2 targets on chromatin. PHF19 target genes are involved in proliferation, differentiation, angiogenesis, and extracellular matrix organization. Depletion of PHF19 triggers an increase in MTF2/PCL2 chromatin recruitment, with a genome-wide gain in PRC2 occupancy and H3K27me3 deposition. Transcriptome analysis shows that PHF19 loss promotes deregulation of key genes involved in growth, metastasis, invasion, and of factors that stimulate blood vessels formation. Consistent with this, PHF19 silencing reduces cell proliferation, while promotes invasive growth and angiogenesis. Our findings reveal a role for PHF19 in controlling the balance between cell proliferation and invasiveness in prostate cancer., This work was suported by the Spanish Ministry of Science and Innovation (BFU2016-75008-P), the Fundación Vencer El Cáncer, the European Regional Development Fund, the Fundación Científica Asociación Española Contra el Cáncer, the Fundació la Marató de TV3, the Agència de Gestió d’Ajuts Universitaris i de Recerca, the Generalitat de Catalunya (Secretaria d’Universitats i Recerca del Departament d’Economia i Coneixement), the Instituto de Salud Carlos III, the European Molecular Biology Laboratory, the Centro de Excelencia Severo Ochoa and the Generalitat de Catalunya (Centres de Recerca de Catalunya)
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

The Polycomb group protein CBX6 is an essential regulator of embryonic stem cell identity

  • Santanach Buxaderas, Alexandra, 1988-
  • Blanco, Enrique
  • Jiang, Hua
  • Molloy, Kelly R.
  • Sansó Martínez, Miriam, 1979-
  • LaCava, John
  • Morey Ramonell, Lluís
  • Di Croce, Luciano
Polycomb group proteins (PcG) are transcriptional repressors that control cell identity and development. In mammals, five different CBX proteins associate with the core Polycomb repressive complex 1 (PRC1). In mouse embryonic stem cells (ESCs), CBX6 and CBX7 are the most highly expressed CBX family members. CBX7 has been recently characterized, but little is known regarding the function of CBX6. Here, we show that CBX6 is essential for ESC identity. Its depletion destabilizes the pluripotency network and triggers differentiation. Mechanistically, we find that CBX6 is physically and functionally associated to both canonical PRC1 (cPRC1) and non-canonical PRC1 (ncPRC1) complexes. Notably, in contrast to CBX7, CBX6 is recruited to chromatin independently of H3K27me3. Taken together, our findings reveal that CBX6 is an essential component of ESC biology that contributes to the structural and functional complexity of the PRC1 complex., This work was supported by grants from the Spanish Ministry of Economy and Competitiveness (BFU2016-75008-P), Centro de Excelencia Severo Ochoa 2013-2017 (SEV-2012-0208), AGAUR, Fundació “La Marató de TV3,” CERCA Programme/Generalitat de Catalunya, and EU FP7 Programs 4DCellFate (277899) to L.D.C. This work aided by collaboration with the National Center for Dynamic Interactome Research and the National Resource for the Mass Spectrometric Analysis of Biological Macromolecules, supported in part by NIH grant P41 GM109824 to Michael P. Rout and grant P41 GM103314 to Brian T. Chait. This paper is subject to the NIH Public Access Policy.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Polycomb factor PHF19 controls cell growth and differentiation toward erythroid pathway in chronic myeloid leukemia cells

  • García Montolío, Marc, 1991-
  • Ballaré, Cecilia Julia
  • Blanco, Enrique
  • Gutiérrez, Arantxa
  • Aranda Aragón, Sergio
  • Gómez, Antonio
  • Kok, Chung H.
  • Yeung, David T.
  • Hughes, Timothy P.
  • Vizán, Pedro
  • Di Croce, Luciano
Polycomb group (PcG) of proteins are a group of highly conserved epigenetic regulators involved in many biological functions, such as embryonic development, cell proliferation, and adult stem cell determination. PHD finger protein 19 (PHF19) is an associated factor of Polycomb repressor complex 2 (PRC2), often upregulated in human cancers. In particular, myeloid leukemia cell lines show increased levels of PHF19, yet little is known about its function. Here, we have characterized the role of PHF19 in myeloid leukemia cells. We demonstrated that PHF19 depletion decreases cell proliferation and promotes chronic myeloid leukemia (CML) differentiation. Mechanistically, we have shown how PHF19 regulates the proliferation of CML through a direct regulation of the cell cycle inhibitor p21. Furthermore, we observed that MTF2, a PHF19 homolog, partially compensates for PHF19 depletion in a subset of target genes, instructing specific erythroid differentiation. Taken together, our results show that PHF19 is a key transcriptional regulator for cell fate determination and could be a potential therapeutic target for myeloid leukemia treatment., This work was supported by grants from the Spanish Ministry of Science and Innovation (BFU2016-75008-P and PID2019-108322GB-100), “Fundación Vencer El Cancer” (VEC), the European Regional Development Fund (FEDER), and from AGAUR (SGR 2017-2019). SA was funded by the Ramon y Cajal program of the Ministerio de Ciencia, Innovación y Universidades, the European Social Fund under the reference number RYC-2018-025002-I, and the Instituto de Salud Carlos III-FEDER (PI19/01814)
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Polycomb complexes in normal and malignant hematopoiesis

  • Di Carlo, Valerio
  • Mocavini, Ivano
  • Di Croce, Luciano
Epigenetic mechanisms are crucial for sustaining cell type-specific transcription programs. Among the distinct factors, Polycomb group (PcG) proteins are major negative regulators of gene expression in mammals. These proteins play key roles in regulating the proliferation, self-renewal, and differentiation of stem cells. During hematopoietic differentiation, many PcG proteins are fundamental for proper lineage commitment, as highlighted by the fact that a lack of distinct PcG proteins results in embryonic lethality accompanied by differentiation biases. Correspondingly, proteins of these complexes are frequently dysregulated in hematological diseases. In this review, we present an overview of the role of PcG proteins in normal and malignant hematopoiesis, focusing on the compositional complexity of PcG complexes, and we briefly discuss the ongoing clinical trials for drugs targeting these factors., Support to the Di Croce laboratory comes from grants from the Spanish Ministry of Economy, Industry, and Competitiveness (BFU2016-75008-P), the European Regional Development Fund (FEDER), Fundacion Vencer El Cancer, and Agència de Gestió d’Ajuts Universitaris i de Recerca; to V. Di Carlo from an ImPuLSe Marie Curie Postdoctoral Fellowship of the European Union Seventh Framework Program (FP7/2007-2013; grant 608959); and I. Mocavini from an FPI fellowship. We acknowledge support of the Spanish Ministry of Economy, Industry, and Competitiveness through the Instituto de Salud Carlos III and for the European Molecular Biology Laboratory partnership; Centro de Excelencia Severo Ochoa; and the Centres de Recerca de Catalunya Program/Generalitat de Catalunya.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

The Polycomb-associated factor PHF19 controls hematopoietic stem cell state and differentiation

  • Vizán, Pedro
  • Gutiérrez, Arantxa
  • Espejo, Isabel
  • García Montolío, Marc, 1991-
  • Lange, Martin
  • Carretero, Ana
  • Lafzi, Atefeh
  • Andrés Aguayo, Luisa de
  • Blanco, Enrique
  • Thambyrajah, Roshana
  • Graf, T. (Thomas)
  • Heyn, Holger
  • Bigas Salvans, Anna
  • Di Croce, Luciano
Adult hematopoietic stem cells (HSCs) are rare multipotent cells in bone marrow that are responsible for generating all blood cell types. HSCs are a heterogeneous group of cells with high plasticity, in part, conferred by epigenetic mechanisms. PHF19, a subunit of the Polycomb repressive complex 2 (PRC2), is preferentially expressed in mouse hematopoietic precursors. Here, we now show that, in stark contrast to results published for other PRC2 subunits, genetic depletion of Phf19 increases HSC identity and quiescence. While proliferation of HSCs is normally triggered by forced mobilization, defects in differentiation impede long-term correct blood production, eventually leading to aberrant hematopoiesis. At molecular level, PHF19 deletion triggers a redistribution of the histone repressive mark H3K27me3, which notably accumulates at blood lineage-specific genes. Our results provide novel insights into how epigenetic mechanisms determine HSC identity, control differentiation, and are key for proper hematopoiesis., The work in the Di Croce laboratory is supported by grants from the Spanish of Economy, Industry, and Competitiveness (MEIC) (BFU2016-75008-P), “Fundación Vencer El Cancer” (VEC), the European Regional Development Fund (FEDER), Fundació “La Marató de TV3,” and from AGAUR. The laboratory of A.B. is supported by SAF2016-75613-R from the Ministerio de Ciencia, Innovación y Universidades. H.H. is a Miguel Servet (CP14/00229) researcher funded by the Spanish Institute of Health Carlos III (ISCIII) and received funding from the European Union’s Horizon 2020 research and innovation programme (MSCA-ITN-2015-675752) and the Ministerio de Ciencia, Innovación y Universidades (SAF2017-89109-P; AEI/FEDER, UE). P.V. was supported by “Fundación Científica de la Asociación Española Contra el Cáncer.”
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

SpikChIP: a novel computational methodology to compare multiple ChIP-seq using spike-in chromatin

  • Blanco, Enrique
  • Di Croce, Luciano
  • Aranda Aragón, Sergio
In order to evaluate cell- and disease-specific changes in the interacting strength of chromatin targets, ChIP-seq signal across multiple conditions must undergo robust normalization. However, this is not possible using the standard ChIP-seq scheme, which lacks a reference for the control of biological and experimental variabilities. While several studies have recently proposed different solutions to circumvent this problem, substantial analytical differences among methodologies could hamper the experimental reproducibility and quantitative accuracy. Here, we propose a computational method to accurately compare ChIP-seq experiments, with exogenous spike-in chromatin, across samples in a genome-wide manner by using a local regression strategy (spikChIP). In contrast to the previous methodologies, spikChIP reduces the influence of sequencing noise of spike-in material during ChIP-seq normalization, while minimizes the overcorrection of non-occupied genomic regions in the experimental ChIP-seq. We demonstrate the utility of spikChIP with both histone and non-histone chromatin protein, allowing us to monitor for experimental reproducibility and the accurate ChIP-seq comparison of distinct experimental schemes. spikChIP software is available on GitHub (https://github.com/eblancoga/spikChIP)., Spanish of Economy, Industry and Competitiveness (MEIC) (BFU2016-75008-P, and PID2019-108322GB-100), “Fundación Vencer El Cancer” (VEC), the European Regional Development Fund (FEDER), and from AGAUR to L.D.C. The Ramon y Cajal program of the Ministerio de Ciencia, Innovación y Universidades and the European Social Fund under the reference number RYC-2018-025002-I, and the Instituto de Salud Carlos III-FEDER (PI19/01814), to S.A. We acknowledge the funding support of the Spanish Ministry of Science and Innovation to the EMBL partnership, the Centro de Excelencia Severo Ochoa and the CERCA Programme / Generalitat de Catalunya.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Chromatin-bound proteome profiling by genome capture

  • Aranda Aragón, Sergio
  • Borràs, Eva
  • Sabidó Aguadé, Eduard, 1981-
  • Di Croce, Luciano
De novo identification of chromatin interactors can reveal unexpected pathways relevant to physiology and human disease. Inspired by the DNA mediated chromatin pull-down (Dm-ChP) technology (also known as iPOND [isolation of proteins on nascent DNA]) for the proteomic characterization of nascent DNA, we have recently reported a new experimental protocol that allows for the identification of proteins on total DNA (iPOTD) for bulk chromatome profiling and de novo identification of chromatin-bound proteins. Here, we detail a step-by-step protocol to survey the cellular chromatin-bound proteome in a simple, robust, and unbiased manner. For complete details on the use and execution of this protocol, please refer to Aranda et al. (2019)., The Proteomics Unit is supported by EPIC-XS, project number 823839, funded by the Horizon 2020 programme of the European Union. The Di Croce Laboratory is supported by grants from the Spanish Ministerio de Educación y Ciencia (BFU2016-75008-P) and by AGAUR.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Trans-generational epigenetic regulation associated with the amelioration of Duchenne Muscular Dystrophy

  • Martone, Julie
  • Lisi, Michela
  • Castagnetti, Francesco
  • Rosa, Alessandro
  • Di Carlo, Valerio
  • Blanco, Enrique
  • Setti, Adriano
  • Mariani, Davide
  • Colantoni, Alessio
  • Santini, Tiziana
  • Perone, Lucia
  • Di Croce, Luciano
  • Bozzoni, Irene
Exon skipping is an effective strategy for the treatment of many Duchenne Muscular Dystrophy (DMD) mutations. Natural exon skipping observed in several DMD cases can help in identifying novel therapeutic tools. Here, we show a DMD study case where the lack of a splicing factor (Celf2a), which results in exon skipping and dystrophin rescue, is due to a maternally inherited trans-generational epigenetic silencing. We found that the study case and his mother express a repressive long non-coding RNA, DUXAP8, whose presence correlates with silencing of the Celf2a coding region. We also demonstrate that DUXAP8 expression is lost upon cell reprogramming and that, upon induction of iPSCs into myoblasts, Celf2a expression is recovered leading to the loss of exon skipping and loss of dystrophin synthesis. Finally, CRISPR/Cas9 inactivation of the splicing factor Celf2a was proven to ameliorate the pathological state in other DMD backgrounds establishing Celf2a ablation or inactivation as a novel therapeutic approach for the treatment of Duchenne Muscular Dystrophy., This work was partially supported by grants from ERC‐2019‐SyG (855923‐ASTRA), Telethon (GGP16213), Parent Project Italia, AIRC (IG 2019 Id. 23053) and PRIN 2017 (2017P352Z4) to I.B.; Spanish Ministry of Economy, Industry and Competitiveness (MEIC) (BFU2016‐75008‐P) to L.D.C. and Sapienza Research Calls (RM118164363B1D21) to J.M.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Interplay between DNA and RNA modifications: a constantly evolving process

  • Di Croce, Luciano
  • Fico, Annalisa
  • Di Croce, Luciano
  • Matarazzo, Maria R.
The epigenome refers to the entirety of DNA methylations, histone modifications, nucleosome occupancy, and coding and non-coding RNAs (and their modifications) in different cell types [...]., This work is supported by Italian Ministry of Education-University-Research (CTN01_00177 Cluster ALISEI_IRMI) and AIRC (IG20736) to Annalisa Fico. The work in the Di Croce laboratory is supported by grants from the Spanish Ministry of Science and Innovation (BFU2016-75008-P, and PID2019-108322GB-100). The work in the Matarazzo laboratory is supported by the grant 2014-2020 FESR F/050011/01-02/X32 PON/MISE
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Polycomb Factor PHF19 Controls Cell Growth and Differentiation Toward Erythroid Pathway in Chronic Myeloid Leukemia Cells

  • García-Montolio, Marc
  • Ballaré, Cecilia
  • Blanco, Enrique
  • Gutiérrez, Arantxa
  • Aranda, Sergi
  • Gomez Moruno, Antonio
Leucèmia mieloide crònica; Diferenciació eritroïdal; Polycomb, Leucemia mieloide crónica; Diferenciación eritroide; Polycomb, Chronic myeloid leukemia; Erythroid differentiation; Polycomb, Polycomb group (PcG) of proteins are a group of highly conserved epigenetic regulators involved in many biological functions, such as embryonic development, cell proliferation, and adult stem cell determination. PHD finger protein 19 (PHF19) is an associated factor of Polycomb repressor complex 2 (PRC2), often upregulated in human cancers. In particular, myeloid leukemia cell lines show increased levels of PHF19, yet little is known about its function. Here, we have characterized the role of PHF19 in myeloid leukemia cells. We demonstrated that PHF19 depletion decreases cell proliferation and promotes chronic myeloid leukemia (CML) differentiation. Mechanistically, we have shown how PHF19 regulates the proliferation of CML through a direct regulation of the cell cycle inhibitor p21. Furthermore, we observed that MTF2, a PHF19 homolog, partially compensates for PHF19 depletion in a subset of target genes, instructing specific erythroid differentiation. Taken together, our results show that PHF19 is a key transcriptional regulator for cell fate determination and could be a potential therapeutic target for myeloid leukemia treatment., This work was supported by the Di Croce Laboratory is supported by grants from the Spanish Ministry of Science and Innovation (BFU2016-75008-P and PID2019-108322GB-100), “Fundación Vencer El Cancer” (VEC), the European Regional Development Fund (FEDER), and from AGAUR (SGR 2017-2019). We acknowledge the support of the Spanish Ministry of Science and Innovation to the EMBL partnership, the Centro de Excelencia Severo Ochoa and the CERCA Programme/Generalitat de Catalunya. PV was supported by the Fundación Científica de la Asociación Española Contra el Cáncer. SA was funded by the Ramon y Cajal program of the Ministerio de Ciencia, Innovación y Universidades, the European Social Fund under the reference number RYC-2018-025002-I, and the Instituto de Salud Carlos III-FEDER (PI19/01814).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Chromatin capture links the metabolic enzyme AHCY to stem cell proliferation

  • Aranda Aragón, Sergio
  • Alcaine Colet, Anna, 1992-
  • Blanco, Enrique
  • Borràs, Eva
  • Caillot, Claire
  • Sabidó Aguadé, Eduard, 1981-
  • Di Croce, Luciano
Profiling the chromatin-bound proteome (chromatome) in a simple, direct, and reliable manner might be key to uncovering the role of yet uncharacterized chromatin factors in physiology and disease. Here, we have designed an experimental strategy to survey the chromatome of proliferating cells by using the DNA-mediated chromatin pull-down (Dm-ChP) technology. Our approach provides a global view of cellular chromatome under normal physiological conditions and enables the identification of chromatin-bound proteins de novo. Integrating Dm-ChP with genomic and functional data, we have discovered an unexpected chromatin function for adenosylhomocysteinase, a major one-carbon pathway metabolic enzyme, in gene activation. Our study reveals a new regulatory axis between the metabolic state of pluripotent cells, ribosomal protein production, and cell division during the early phase of embryo development, in which the metabolic flux of methylation reactions is favored in a local milieu., We acknowledge support from the Spanish Ministry of Economy, Industry and Competitiveness to the EMBL partnership, Centro de Excelencia Severo Ochoa, the CERCA Programme/Generalitat de Catalunya, the Secretary for Universities and Research of the Ministry of Economy and Knowledge of the Government of Catalonia (to S.A. and A.A.-C.). The CRG/UPF Proteomics Unit is a member of the ProteoRed PRB3 consortium that was supported by grant PT17/0019 of the PE I+D+i 2013–2016 from the Instituto de Salud Carlos III (ISCIII), ERDF, and “Secretaria d’Universitats i Recerca del Departament d’Economia i Coneixement de la Generalitat de Catalunya” (2017SGR595). The Di Croce Laboratory was supported by grants from the Spanish Ministerio de Educación y Ciencia (BFU2016-75008-P), AGAUR, and La Marato TV3
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

The changing chromatome as a driver of disease: a panoramic view from different methodologies

  • Espejo, Isabel
  • Di Croce, Luciano
  • Aranda Aragón, Sergio
Chromatin-bound proteins underlie several fundamental cellular functions, such as control of gene expression and the faithful transmission of genetic and epigenetic information. Components of the chromatin proteome (the "chromatome") are essential in human life, and mutations in chromatin-bound proteins are frequently drivers of human diseases, such as cancer. Proteomic characterization of chromatin and de novo identification of chromatin interactors could, thus, reveal important and perhaps unexpected players implicated in human physiology and disease. Recently, intensive research efforts have focused on developing strategies to characterize the chromatome composition. In this review, we provide an overview of the dynamic composition of the chromatome, highlight the importance of its alterations as a driving force in human disease (and particularly in cancer), and discuss the different approaches to systematically characterize the chromatin-bound proteome in a global manner., I.E. is supported by La CaixaINPhINIT program. L.D.C is supported by grants from the Spanish of Economy, Industry and Competitiveness (MEIC) (BFU2016‐75008‐P), “FundaciónVencer El Cancer” (VEC), the European Regional Development Fund (FEDER), Fundació “La Marató de TV3”, and from AGAUR. S.A. is funded by Ramón y Cajal Program MICIU‐FSE (RYC2018‐025002‐I) and ISCIII‐FEDER (PI19/01814)
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

The bivalent genome: characterization, structure, and regulation

  • Blanco, Enrique
  • González Ramírez, Mar, 1991-
  • Alcaine Colet, Anna, 1992-
  • Aranda Aragón, Sergio
  • Di Croce, Luciano
An intricate molecular machinery is at the core of gene expression regulation in every cell. During the initial stages of organismal development, the coordinated activation of diverse transcriptional programs is crucial and must be carefully executed to shape every organ and tissue. Bivalent promoters and poised enhancers are regulatory regions decorated with histone marks that are associated with both positive and negative transcriptional outcomes. These apparently contradictory signals are important for setting bivalent genes in a poised state, which is subsequently resolved during differentiation into either active or repressive states. We discuss the origins of bivalent promoters and the mechanisms implicated in their acquisition and maintenance. We further review how the presence of bivalent marks influences genome architecture. Finally, we highlight the potential link between bivalency and cancer which could drive biomedical research in disease etiology and treatment., Work in the laboratory of L.D.C. is supported by grants from the Spanish of Economy, Industry, and Competitiveness (MEIC; BFU2016-75008-P), the Fundacion Vencer El Cancer (VEC), the European Regional Development Fund (FEDER), and the Catalan Agency for Management of University and Research Grants (AGAUR). We also acknowledge support from the MEIC (through the Instituto de Salud Carlos III and an EMBL partnership), the Centro de Excelencia Severo Ochoa, and the CERCA Programme/Generalitat de Catalunya.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Epigenomic profiling of primate lymphoblastoid cell lines reveals the evolutionary patterns of epigenetic activities in gene regulatory architectures

  • García Perez, Raquel|||0000-0002-2573-6984
  • Esteller-Cucala, Paula|||0000-0003-3048-4280
  • Mas, Glòria
  • Lobón, Irene|||0000-0003-1170-9915
  • Di Carlo, Valerio|||0000-0002-5099-0685
  • Riera, Meritxell
  • Kuhlwilm, Martin|||0000-0002-0115-1797
  • Navarro, Arcadi|||0000-0003-2162-8246
  • Blancher, Antoine|||0000-0002-6763-0539
  • Di Croce, Luciano|||0000-0003-3488-6228
  • Gomez-Skarmeta, José Luis
  • Juan, David|||0000-0003-1912-9667
  • Marquès i Bonet, Tomàs|||0000-0002-5597-3075
Changes in the epigenetic regulation of gene expression have a central role in evolution. Here, we extensively profiled a panel of human, chimpanzee, gorilla, orangutan, and macaque lymphoblastoid cell lines (LCLs), using ChIP-seq for five histone marks, ATAC-seq and RNA-seq, further complemented with whole genome sequencing (WGS) and whole genome bisulfite sequencing (WGBS). We annotated regulatory elements (RE) and integrated chromatin contact maps to define gene regulatory architectures, creating the largest catalog of RE in primates to date. We report that epigenetic conservation and its correlation with sequence conservation in primates depends on the activity state of the regulatory element. Our gene regulatory architectures reveal the coordination of different types of components and highlight the role of promoters and intragenic enhancers (gE) in the regulation of gene expression. We observe that most regulatory changes occur in weakly active gE. Remarkably, novel human-specific gE with weak activities are enriched in human-specific nucleotide changes. These elements appear in genes with signals of positive selection and human acceleration, tissue-specific expression, and particular functional enrichments, suggesting that the regulatory evolution of these genes may have contributed to human adaptation.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

The Polycomb-associated factor PHF19 controls hematopoietic stem cell state and differentiation

  • Vizán, Pedro|||0000-0002-6787-9940
  • Gutiérrez, Arantxa|||0000-0001-9033-3834
  • Espejo, Isabel
  • García-Montolio, Marc
  • Lange, Martin|||0000-0002-4045-3915
  • Carretero i Romay, Ana|||0000-0001-9377-4926
  • Lafzi, Atefeh|||0000-0003-4237-4847
  • de Andrés-Aguayo, Luisa|||0000-0001-6717-242X
  • Blanco, Enrique|||0000-0001-6261-7370
  • Thambyrajah, Roshana|||0000-0002-3941-760X
  • Graf, Thomas|||0000-0003-2774-4117
  • Heyn, Holger|||0000-0002-3276-1889
  • Bigas Salvans, Anna|||0000-0003-4801-6899
  • Di Croce, Luciano|||0000-0003-3488-6228
Phf19, a Polycomb subunit, controls hematopoietic stem cells identity and differentiation. Adult hematopoietic stem cells (HSCs) are rare multipotent cells in bone marrow that are responsible for generating all blood cell types. HSCs are a heterogeneous group of cells with high plasticity, in part, conferred by epigenetic mechanisms. PHF19, a subunit of the Polycomb repressive complex 2 (PRC2), is preferentially expressed in mouse hematopoietic precursors. Here, we now show that, in stark contrast to results published for other PRC2 subunits, genetic depletion of Phf19 increases HSC identity and quiescence. While proliferation of HSCs is normally triggered by forced mobilization, defects in differentiation impede long-term correct blood production, eventually leading to aberrant hematopoiesis. At molecular level, PHF19 deletion triggers a redistribution of the histone repressive mark H3K27me3, which notably accumulates at blood lineage-specific genes. Our results provide novel insights into how epigenetic mechanisms determine HSC identity, control differentiation, and are key for proper hematopoiesis.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Polycomb Factor PHF19 Controls Cell Growth and Differentiation Toward Erythroid Pathway in Chronic Myeloid Leukemia Cells

  • García-Montolio, Marc
  • Ballaré, Cecilia
  • Blanco, Enrique
  • Gutiérrez, Arantxa
  • Aranda, Sergi
  • Gomez Moruno, Antonio
Leucèmia mieloide crònica; Diferenciació eritroïdal; Polycomb, Leucemia mieloide crónica; Diferenciación eritroide; Polycomb, Chronic myeloid leukemia; Erythroid differentiation; Polycomb, Polycomb group (PcG) of proteins are a group of highly conserved epigenetic regulators involved in many biological functions, such as embryonic development, cell proliferation, and adult stem cell determination. PHD finger protein 19 (PHF19) is an associated factor of Polycomb repressor complex 2 (PRC2), often upregulated in human cancers. In particular, myeloid leukemia cell lines show increased levels of PHF19, yet little is known about its function. Here, we have characterized the role of PHF19 in myeloid leukemia cells. We demonstrated that PHF19 depletion decreases cell proliferation and promotes chronic myeloid leukemia (CML) differentiation. Mechanistically, we have shown how PHF19 regulates the proliferation of CML through a direct regulation of the cell cycle inhibitor p21. Furthermore, we observed that MTF2, a PHF19 homolog, partially compensates for PHF19 depletion in a subset of target genes, instructing specific erythroid differentiation. Taken together, our results show that PHF19 is a key transcriptional regulator for cell fate determination and could be a potential therapeutic target for myeloid leukemia treatment., This work was supported by the Di Croce Laboratory is supported by grants from the Spanish Ministry of Science and Innovation (BFU2016-75008-P and PID2019-108322GB-100), “Fundación Vencer El Cancer” (VEC), the European Regional Development Fund (FEDER), and from AGAUR (SGR 2017-2019). We acknowledge the support of the Spanish Ministry of Science and Innovation to the EMBL partnership, the Centro de Excelencia Severo Ochoa and the CERCA Programme/Generalitat de Catalunya. PV was supported by the Fundación Científica de la Asociación Española Contra el Cáncer. SA was funded by the Ramon y Cajal program of the Ministerio de Ciencia, Innovación y Universidades, the European Social Fund under the reference number RYC-2018-025002-I, and the Instituto de Salud Carlos III-FEDER (PI19/01814).